173 related articles for article (PubMed ID: 29900011)
21. Oral vaccination with influenza hemagglutinin combined with human pulmonary surfactant-mimicking synthetic adjuvant SF-10 induces efficient local and systemic immunity compared with nasal and subcutaneous vaccination and provides protective immunity in mice.
Kimoto T; Kim H; Sakai S; Takahashi E; Kido H
Vaccine; 2019 Jan; 37(4):612-622. PubMed ID: 30553569
[TBL] [Abstract][Full Text] [Related]
22. Enhancement of immune response and protection in BALB/c mice immunized with liposomal recombinant major surface glycoprotein of Leishmania (rgp63): the role of bilayer composition.
Badiee A; Jaafari MR; Khamesipour A; Samiei A; Soroush D; Kheiri MT; Barkhordari F; McMaster WR; Mahboudi F
Colloids Surf B Biointerfaces; 2009 Nov; 74(1):37-44. PubMed ID: 19615870
[TBL] [Abstract][Full Text] [Related]
23. Vaccination with liposomal leishmanial antigens adjuvanted with monophosphoryl lipid-trehalose dicorynomycolate (MPL-TDM) confers long-term protection against visceral leishmaniasis through a human administrable route.
Ravindran R; Maji M; Ali N
Mol Pharm; 2012 Jan; 9(1):59-70. PubMed ID: 22133194
[TBL] [Abstract][Full Text] [Related]
24. Mucosal immunization with purified flagellin from Salmonella induces systemic and mucosal immune responses in C3H/HeJ mice.
Strindelius L; Filler M; Sjöholm I
Vaccine; 2004 Sep; 22(27-28):3797-808. PubMed ID: 15315861
[TBL] [Abstract][Full Text] [Related]
25. Induction of systemic and mucosal immune responses to human immunodeficiency virus type 1 by a DNA vaccine formulated with QS-21 saponin adjuvant via intramuscular and intranasal routes.
Sasaki S; Sumino K; Hamajima K; Fukushima J; Ishii N; Kawamoto S; Mohri H; Kensil CR; Okuda K
J Virol; 1998 Jun; 72(6):4931-9. PubMed ID: 9573261
[TBL] [Abstract][Full Text] [Related]
26. IgG2 antibodies against a clinical grade Plasmodium falciparum CSP vaccine antigen associate with protection against transgenic sporozoite challenge in mice.
Schwenk R; DeBot M; Porter M; Nikki J; Rein L; Spaccapelo R; Crisanti A; Wightman PD; Ockenhouse CF; Dutta S
PLoS One; 2014; 9(10):e111020. PubMed ID: 25343487
[TBL] [Abstract][Full Text] [Related]
27. Lipid conjugation of TLR7 agonist Resiquimod ensures co-delivery with the liposomal Cationic Adjuvant Formulation 01 (CAF01) but does not enhance immunopotentiation compared to non-conjugated Resiquimod+CAF01.
Wilkinson A; Lattmann E; Roces CB; Pedersen GK; Christensen D; Perrie Y
J Control Release; 2018 Dec; 291():1-10. PubMed ID: 30291987
[TBL] [Abstract][Full Text] [Related]
28. Liposomal co-encapsulation of a novel gemini lipopeptide and a CpG-ODN induces a strong Th1 response with the co-activation of a Th2/Th17 profile and high antibody levels.
Reidel IG; Curti CC; Dorémus L; Béré E; Delwail A; Russi RC; Lecron JC; Morel F; García MI; Müller DM; Jégou JF; Veaute CM
Vaccine; 2024 Mar; 42(8):1953-1965. PubMed ID: 38378388
[TBL] [Abstract][Full Text] [Related]
29. Incorporation of Toll-Like Receptor Ligands and Inflammasome Stimuli in GM3 Liposomes to Induce Dendritic Cell Maturation and T Cell Responses.
Nijen Twilhaar MK; Czentner L; Bouma RG; Olesek K; Grabowska J; Wang AZ; Affandi AJ; Belt SC; Kalay H; van Nostrum CF; van Kooyk Y; Storm G; den Haan JMM
Front Immunol; 2022; 13():842241. PubMed ID: 35251040
[TBL] [Abstract][Full Text] [Related]
30. gp63 in stable cationic liposomes confers sustained vaccine immunity to susceptible BALB/c mice infected with Leishmania donovani.
Bhowmick S; Ravindran R; Ali N
Infect Immun; 2008 Mar; 76(3):1003-15. PubMed ID: 18195029
[TBL] [Abstract][Full Text] [Related]
31. Potentiating effects of MPL on DSPC bearing cationic liposomes promote recombinant GP63 vaccine efficacy: high immunogenicity and protection.
Mazumder S; Maji M; Ali N
PLoS Negl Trop Dis; 2011 Dec; 5(12):e1429. PubMed ID: 22206029
[TBL] [Abstract][Full Text] [Related]
32. Adjuvanting a Simian Immunodeficiency Virus Vaccine with Toll-Like Receptor Ligands Encapsulated in Nanoparticles Induces Persistent Antibody Responses and Enhanced Protection in TRIM5α Restrictive Macaques.
Kasturi SP; Kozlowski PA; Nakaya HI; Burger MC; Russo P; Pham M; Kovalenkov Y; Silveira ELV; Havenar-Daughton C; Burton SL; Kilgore KM; Johnson MJ; Nabi R; Legere T; Sher ZJ; Chen X; Amara RR; Hunter E; Bosinger SE; Spearman P; Crotty S; Villinger F; Derdeyn CA; Wrammert J; Pulendran B
J Virol; 2017 Feb; 91(4):. PubMed ID: 27928002
[TBL] [Abstract][Full Text] [Related]
33. Induction of mucosal immune responses by administration of liposome-antigen formulations and interleukin-12.
Baca-Estrada ME; Foldvari M; Snider M
J Interferon Cytokine Res; 1999 May; 19(5):455-62. PubMed ID: 10386857
[TBL] [Abstract][Full Text] [Related]
34. Toll like-receptor agonist Pam
Kennerknecht K; Noschka R; Löffler F; Wehrstedt S; Pedersen GK; Mayer D; Grieshober M; Christensen D; Stenger S
Med Microbiol Immunol; 2020 Apr; 209(2):163-176. PubMed ID: 32020284
[TBL] [Abstract][Full Text] [Related]
35. A Liposome-Based Adjuvant Containing Two Delivery Systems with the Ability to Induce Mucosal Immunoglobulin A Following a Parenteral Immunization.
Christensen D; Bøllehuus Hansen L; Leboux R; Jiskoot W; Christensen JP; Andersen P; Dietrich J
ACS Nano; 2019 Feb; 13(2):1116-1126. PubMed ID: 30609354
[TBL] [Abstract][Full Text] [Related]
36. An alphavirus-based adjuvant enhances serum and mucosal antibodies, T cells, and protective immunity to influenza virus in neonatal mice.
Khalil SM; Tonkin DR; Snead AT; Parks GD; Johnston RE; White LJ
J Virol; 2014 Aug; 88(16):9182-96. PubMed ID: 24899195
[TBL] [Abstract][Full Text] [Related]
37. Comparison of BCG, MPL and cationic liposome adjuvant systems in leishmanial antigen vaccine formulations against murine visceral leishmaniasis.
Ravindran R; Bhowmick S; Das A; Ali N
BMC Microbiol; 2010 Jun; 10():181. PubMed ID: 20576102
[TBL] [Abstract][Full Text] [Related]
38. Oral but not parenteral interleukin (IL)-12 redirects T helper 2 (Th2)-type responses to an oral vaccine without altering mucosal IgA responses.
Marinaro M; Boyaka PN; Finkelman FD; Kiyono H; Jackson RJ; Jirillo E; McGhee JR
J Exp Med; 1997 Feb; 185(3):415-27. PubMed ID: 9053442
[TBL] [Abstract][Full Text] [Related]
39. Liposomal immunostimulatory DNA sequence (ISS-ODN): an efficient parenteral and mucosal adjuvant for influenza and hepatitis B vaccines.
Joseph A; Louria-Hayon I; Plis-Finarov A; Zeira E; Zakay-Rones Z; Raz E; Hayashi T; Takabayashi K; Barenholz Y; Kedar E
Vaccine; 2002 Sep; 20(27-28):3342-54. PubMed ID: 12213404
[TBL] [Abstract][Full Text] [Related]
40. Protective effect of antigen delivery using monoolein-based liposomes in experimental hematogenously disseminated candidiasis.
Carneiro C; Correia A; Lima T; Vilanova M; Pais C; Gomes AC; Real Oliveira MECD; Sampaio P
Acta Biomater; 2016 Jul; 39():133-145. PubMed ID: 27150234
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
